Clinical Trials Insight: 700030561
Latest Information Update: 23 Apr 2008
Price :
$35 *
At a glance
- Drugs VX 813 (Primary)
- Indications Hepatitis C
- Focus Adverse reactions
- 22 Apr 2008 The trial is expected to be initiated in the second half of 2008.
- 13 Feb 2008 New trial record.